Cargando…

The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia

BACKGROUND: Preeclampsia is a pregnancy-specific disorder that is associated with an increase in blood pressure and proteinuria; in severe cases, it can cause platelet abnormalities. Silymarin is the extract of Silybum marianum, which is recognized as a safe antioxidant drug. OBJECTIVE: To determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Baghbahadorani, Fahimeh Kaveh, Miraj, Sepideh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Electronic physician 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930266/
https://www.ncbi.nlm.nih.gov/pubmed/27382456
http://dx.doi.org/10.19082/2436
_version_ 1782440725903835136
author Baghbahadorani, Fahimeh Kaveh
Miraj, Sepideh
author_facet Baghbahadorani, Fahimeh Kaveh
Miraj, Sepideh
author_sort Baghbahadorani, Fahimeh Kaveh
collection PubMed
description BACKGROUND: Preeclampsia is a pregnancy-specific disorder that is associated with an increase in blood pressure and proteinuria; in severe cases, it can cause platelet abnormalities. Silymarin is the extract of Silybum marianum, which is recognized as a safe antioxidant drug. OBJECTIVE: To determine the impact of Silymarin on the improvement of severe preeclampsia in 60 patients with severe preeclampsia. METHODS: In this double-blind clinical trial study, This study included 60 patients whose pregnancies were terminated because of severe preeclampsia and who were referred to Hajar Hospital in Shahrekord, Iran, from April 2014 to September 2015. The patients were divided randomly into two groups, i.e., a group of 30 patients and a control group of 30 patients. In addition to the current treatments for preeclampsia, The members of the study group were administered 70 mg of Silymarin at three hours and 24 hours after the termination of their pregnancies. The control group received a placebo at the same times. Platelet count tests were compared at the baseline and at 12, 36, and 60 hours post-measurements in the two groups by SPSS software, version 22, by the ANOVA test, and by the independent-samples t-test. RESULTS: At the baseline, the two groups were not significantly different in terms of various criteria, such as age, BMI, and platelet counts. There were no significant differences between the two groups regarding the number of platelets at 12, 36, and 60 h after their pregnancies were ended (p > 0.01). CONCLUSIONS: The results of this study indicated that, although oxidative factors are involved in the incidence of complications of preeclampsia, e.g., thrombocytopenia, merely using an oxidative agent does not alleviate this effect. This indicated that other factors likely are involved in the pathogenesis of this disease. Additional studies are needed to prove the beneficial effects of this drug in the treatment of preeclampsia. CLINICAL TRIAL REGISTRATION: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT201509042388/N1. FUNDING: Shahrekord University of Medical Sciences supported this research (project no. 2006).
format Online
Article
Text
id pubmed-4930266
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Electronic physician
record_format MEDLINE/PubMed
spelling pubmed-49302662016-07-05 The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia Baghbahadorani, Fahimeh Kaveh Miraj, Sepideh Electron Physician Original Article BACKGROUND: Preeclampsia is a pregnancy-specific disorder that is associated with an increase in blood pressure and proteinuria; in severe cases, it can cause platelet abnormalities. Silymarin is the extract of Silybum marianum, which is recognized as a safe antioxidant drug. OBJECTIVE: To determine the impact of Silymarin on the improvement of severe preeclampsia in 60 patients with severe preeclampsia. METHODS: In this double-blind clinical trial study, This study included 60 patients whose pregnancies were terminated because of severe preeclampsia and who were referred to Hajar Hospital in Shahrekord, Iran, from April 2014 to September 2015. The patients were divided randomly into two groups, i.e., a group of 30 patients and a control group of 30 patients. In addition to the current treatments for preeclampsia, The members of the study group were administered 70 mg of Silymarin at three hours and 24 hours after the termination of their pregnancies. The control group received a placebo at the same times. Platelet count tests were compared at the baseline and at 12, 36, and 60 hours post-measurements in the two groups by SPSS software, version 22, by the ANOVA test, and by the independent-samples t-test. RESULTS: At the baseline, the two groups were not significantly different in terms of various criteria, such as age, BMI, and platelet counts. There were no significant differences between the two groups regarding the number of platelets at 12, 36, and 60 h after their pregnancies were ended (p > 0.01). CONCLUSIONS: The results of this study indicated that, although oxidative factors are involved in the incidence of complications of preeclampsia, e.g., thrombocytopenia, merely using an oxidative agent does not alleviate this effect. This indicated that other factors likely are involved in the pathogenesis of this disease. Additional studies are needed to prove the beneficial effects of this drug in the treatment of preeclampsia. CLINICAL TRIAL REGISTRATION: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT201509042388/N1. FUNDING: Shahrekord University of Medical Sciences supported this research (project no. 2006). Electronic physician 2016-05-25 /pmc/articles/PMC4930266/ /pubmed/27382456 http://dx.doi.org/10.19082/2436 Text en © 2016 The Authors This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/3.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Original Article
Baghbahadorani, Fahimeh Kaveh
Miraj, Sepideh
The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
title The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
title_full The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
title_fullStr The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
title_full_unstemmed The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
title_short The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
title_sort impact of silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930266/
https://www.ncbi.nlm.nih.gov/pubmed/27382456
http://dx.doi.org/10.19082/2436
work_keys_str_mv AT baghbahadoranifahimehkaveh theimpactofsilymarinonimprovementofplateletabnormalitiesinpatientswithseverepreeclampsia
AT mirajsepideh theimpactofsilymarinonimprovementofplateletabnormalitiesinpatientswithseverepreeclampsia
AT baghbahadoranifahimehkaveh impactofsilymarinonimprovementofplateletabnormalitiesinpatientswithseverepreeclampsia
AT mirajsepideh impactofsilymarinonimprovementofplateletabnormalitiesinpatientswithseverepreeclampsia